Search results
We’re on the road with a new approach to clinical trials—one that expands access to cutting-edge medicines and treatments. Lilly is a medicine company turning science into healing to make life better for people around the world.
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
We’re a medicine company turning science into healing to make life better for people around the world. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing science to solve some of the world's most significant health challenges.
Eli Lilly and Company works tirelessly to develop and deliver trusted medicines that meet real needs. These include Trulicity, Humalog, Alimta, Forteo, Taltz, Humulin, Basaglar, Jardiance, Cyramza, REYVOW, Verzenio, Emgality and more.
The Investor Relations website contains information about Eli Lilly and Company's business for stockholders, potential investors, and financial analysts.
Mar 31, 2024 · Lilly at a Glance. A heritage 148 years strong: company founded on May 10, 1876. Headquarters located in Indianapolis, Indiana, U.S.A. More than 44,000 employees worldwide. Approximately 10,000 employees engaged in research and development. Clinical research conducted in more than 55 countries.
Jul 2, 2024 · INDIANAPOLIS , June 25, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced a collaboration with OpenAI that will allow Lilly to leverage OpenAI 's generative AI to invent novel antimicrobials to treat drug-resistant pathogens.
Eli Lilly and Company | 1,831,480 followers on LinkedIn. We're a medicine company turning science into healing to make life better for people around the world.
Aug 8, 2023 · Eli Lilly on Tuesday raised its annual forecasts as demand for new diabetes drug Mounjaro surges ahead of a decision on its use as a weight-loss treatment, with shares soaring 18% to a record...
Apr 30, 2024 · Lilly Reports First-Quarter 2024 Financial Results and Raises Full-Year Revenue Guidance by $2 Billion, Highlights Pipeline Momentum. Revenue in Q1 2024 increased 26%, driven by Mounjaro, Zepbound, Verzenio and Jardiance. Pipeline progress included positive results from two Phase 3 trials of tirzepatide for obstructive sleep apnea; submission ...
